XDx, a molecular diagnostics company, today announced its AlloMap® molecular expression test will be the subject of presentations and discussions at the American Transplant Congress 2007.
The test, currently used to detect the absence of heart transplant rejection instead of routine invasive heart muscle biopsies, has now been shown to correlate with oxygen saturation levels, cardiac filling pressures, and the electrical properties of the transplanted heart.
Also, data from the Lung Allograft Rejection Gene expression Observation (LARGO) study presented at the ATC sessions demonstrate that a non-invasive blood test can detect cytomegalovirus-induced immune responses in lung transplant patients.